Copyright
©The Author(s) 2023.
World J Clin Cases. Jan 26, 2023; 11(3): 506-513
Published online Jan 26, 2023. doi: 10.12998/wjcc.v11.i3.506
Published online Jan 26, 2023. doi: 10.12998/wjcc.v11.i3.506
Ref. | Type of stem cells | Number of cases | Mean age (year) | Methods of treatment | Possible mechanism | Outcome | Adverse events | Conciusion |
Uzun et al[49], 2021 | ADMSCs | 10 | 57.5 | Intralesional injection | The release of angiogenic cytokines, increasing epithelialization, granulation tissue formation, anti-inflammatory, and anti-apoptotic effects | Time to wound closure (d): ADMSCs group (n = 10): 31.0 ± 10.7; Control group (n = 10): 54.8 ± 15.0; P = 0.002 | No found | Allogeneic ADMSCs injection is a safe and effective method with a positive contribution to wound-healing time in the treatment of chronic diabetic foot ulcers |
Suzdaltseva et al[51], 2020 | UCMSCs | 31 | 58.5 | Intralesional injection | The release of angiogenic cytokines, cell differentiation, and immunomodulation | Complete wound closure or significant improvement (% in group)a: UCMSCs group (n = 59): 22%; Placebo group (n = 49): 8.2%; P < 0.05 | No found | Locally delivered allogeneic UCMSCs can contribute to chronic wound repair and provide an additional support toward new therapeutic strategies |
Moon et al[50], 2019 | ADMSCs | 30 | 59.9 | Topical | Synthesizing higher amounts of collagen, fibroblast growth factor, and vascular endothelial growth factor in vitro | Complete wound closure at Week 12 (% in group): ADMSCs group (n = 30): 82%; Control group (n = 29): 53%; P < 0.05 | No found | Allogeneic ADMSCs might be effective and safe to treat diabetic foot ulcers |
Chen et al[53], 2018 | BMMSCs | 1 | 64 | Intramuscular injection | The release of angiogenic cytokines, differentiation and angiogen | No recurrence in the next 10-yr follow-up span | No found | Autologous BMMSC transplantation therapy may be an effective measure for recurrent bullosis diabeticorum |
Qin et al[52], 2016 | UCMSCs | 28 | 75 | Intravascular and intralesional injection | The release of signalling or growth factors, and differentiation of injected precursor cells into functional tissue | Increased number of vessels: Experimental group (n = 28): 9.3 ± 2.7; Control group (n = 25): 5.9 ± 3.3; P < 0.05 | No found | UCMSC transplantation after angioplasty is a safe and effective clinical therapy for severe diabetic foot |
Xu et al[55], 2016 | Peripheral blood stem cells | 63 | 69 | Intralesional injection | Angiogenesis and vascularization | CTA scoreb: Pre-transplantation (n = 63): 1.22 ± 0.15; Post-transplantation (n = 63): 2.35 ± 0.784; P < 0.01 | No found | Autologous peripheral blood stem cell transplantation can promote the establishment of collateral circulation in patients with diabetic foot |
Lu et al[54], 2011 | BMMSCs | 18 | 63 | Intramuscular injection | The release of angiogenic cytokines, differentiation and angiogenesis | Angiographic score of MRA in limbs at 24 wkb: BMMSCs (n = 18): 1.9 ± 0.5; BMMNCs (n = 19): 1.5 ± 0.6; P = 0.018 | No found | BMMSCs therapy may be better tolerated and more effective than BMMNCs for increasing lower limb perfusion and promoting foot ulcer healing in diabetic patients with critical limb ischemia |
- Citation: Xu ZH, Ma MH, Li YQ, Li LL, Liu GH. Progress and expectation of stem cell therapy for diabetic wound healing. World J Clin Cases 2023; 11(3): 506-513
- URL: https://www.wjgnet.com/2307-8960/full/v11/i3/506.htm
- DOI: https://dx.doi.org/10.12998/wjcc.v11.i3.506